Document is current

Any future updates will be listed below

821 The potential clinical usage of Fc-optimized anti-CCR8 therapeutic antibodies as a monotherapy or combined with other promising immune-modulating agents beyond PD-1/L1

Crossref DOI link: https://doi.org/10.1136/jitc-2022-SITC2022.0821

Published Online: 2022-11-07

Published Print: 2022-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

About CrossMark